New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Last Close
Oct 17  •  12:02PM ET
1.54
Dollar change
-0.02
Percentage change
-1.28
%
Index- P/E- EPS (ttm)-4.88 Insider Own8.37% Shs Outstand12.50M Perf Week1.32%
Market Cap19.25M Forward P/E- EPS next Y-2.01 Insider Trans0.00% Shs Float11.45M Perf Month-10.47%
Enterprise Value41.58M PEG- EPS next Q-0.58 Inst Own34.48% Short Float1.30% Perf Quarter-11.49%
Income-38.92M P/S1.69 EPS this Y62.30% Inst Trans-1.50% Short Ratio2.12 Perf Half Y17.56%
Sales11.40M P/B- EPS next Y22.51% ROA-97.73% Short Interest0.15M Perf YTD-49.67%
Book/sh-1.31 P/C1.90 EPS next 5Y44.09% ROE-2951.24% 52W High5.45 -71.74% Perf Year-71.21%
Cash/sh0.81 P/FCF- EPS past 3/5Y11.49% 18.70% ROIC-394.64% 52W Low1.02 50.98% Perf 3Y-89.45%
Dividend Est.- EV/EBITDA- Sales past 3/5Y0.80% 1.75% Gross Margin97.83% Volatility9.06% 6.44% Perf 5Y-93.69%
Dividend TTM- EV/Sales3.65 EPS Y/Y TTM40.74% Oper. Margin-332.92% ATR (14)0.11 Perf 10Y-99.22%
Dividend Ex-Date- Quick Ratio0.74 Sales Y/Y TTM12.24% Profit Margin-341.25% RSI (14)42.41 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.74 EPS Q/Q66.45% SMA20-4.44% Beta3.89 Target Price16.33
Payout- Debt/Eq- Sales Q/Q7.97% SMA50-7.32% Rel Volume0.55 Prev Close1.56
Employees34 LT Debt/Eq- EarningsAug 05 BMO SMA200-30.33% Avg Volume70.24K Price1.54
IPOAug 01, 2000 Option/ShortNo / Yes EPS/Sales Surpr.50.00% 4.17% Trades Volume16,888 Change-1.28%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $17
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Oct-03-25 04:00PM
Sep-02-25 10:43AM
Aug-06-25 11:00AM
Aug-05-25 09:10AM
08:08AM
08:00AM Loading…
08:00AM
Aug-04-25 10:13AM
Jul-29-25 08:30AM
Jul-02-25 08:32AM
May-07-25 03:07AM
May-06-25 06:16PM
09:05AM
08:13AM
08:00AM
May-05-25 10:26AM
10:01AM Loading…
May-01-25 10:01AM
Apr-29-25 08:00AM
Apr-12-25 11:00AM
Apr-02-25 04:05PM
Apr-01-25 03:01AM
01:42AM
Mar-31-25 09:59AM
08:16AM
08:00AM
Mar-28-25 04:07PM
Dec-10-24 08:00AM
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM Loading…
08:00AM
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
08:00AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
May-04-23 05:45PM
04:26PM
04:01PM
Apr-27-23 04:01PM
Apr-17-23 08:12AM
Apr-05-23 08:13PM
Apr-03-23 08:00AM
Mar-14-23 11:02AM
Mar-13-23 10:21PM
09:15AM
08:00AM
Mar-08-23 07:09PM
Mar-02-23 04:01PM
Jan-20-23 10:09AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.